DEBIOPHARM GROUP – STRATEGICALLY FOCUSED ON NARROW-SPECTRUM ANTIBIOTICS

An overview of the company, its business model, pipeline with a focus on the Fabiotics Platform

DEBIOPHARM GROUP PRESENTAION

Debiopharm Group Structure

Founded in 1979, Debiopharm is a Swiss-based global bio-pharmaceutical group of four companies active in drug development, GMP manufacturing of proprietary drugs, diagnostics, and investments. Debiopharm International SA is focused on the development of prescription drugs that target unmet medical needs. The company in-licenses, develops promising drug candidates. The products are commercialized by pharmaceutical out-licensing partners to give access to the largest number of patients worldwide.



Business Model



Deal Focus

Main Therapeutic areas:
Oncology
Infectious Diseases
Immunology

Development stages:
Early & Late Preclinical
Clinical (Phases I, II, III)

Molecules:
NCEs
NBEs

OUR APPROACH TO ANTIBIOTICS

Transition Towards Narrow-Spectrum Antibiotics



Clinical Development Projects

Program	Originator Country	Indication	Mode of Action	Discovery	Preclinical	Phase I	Phase II	Phase III
Debio 025 Alisporivir	Internal research	Hepatitis C	Cyclophilin inhibitor					
Debio 1452	Fabiotics Platform[1]	Infectious diseases *Staph.*	FabI inhibitor					
Debio 1450	Fabiotics Platform[1]	ABSSSI	FabI inhibitor					
Debio 0932	Being developed by Curis	Oncology	Hsp90 inhibitor					
Debio 1143[2]	Ascenta (USA)	Head & Neck cancer	SMAC mimetic					
Debio 1143[2]	Ascenta (USA)	Indication screening	SMAC mimetic					
Debio 1347	Chugai (Japan)	Oncology	FGFR 1, 2, 3 inhibitor					
Debio 06178	Aurigene (India)	Oncology	Multikinase inhibitor					
Debio 1144	Being developed by Ascepion	Oncology	Tyrosine kinase inhibitor					

[1] Debiopharm's platform
[2] Phase I-II

Drug Discovery Projects

Program	Originator Country	Indication	Mode of Action	Entry Indication Screening: Discovery (Hits, H2L, LO, DC Select)	Preclinical	Phase I
Debio 0929	MSM (USA)	Oncology	Innovative target			
Debio 0826	EPFL (CH)	Oncology	Notch Pathway Inhibitor			
Debio 1036B	Yale (USA)	Autoimmune diseases	MIF Inhibitor			
Debio 0930B	Mercury (USA)	Metabolic disorders	AMPK activator			
Debio 1449	ETC/A*STAR (Singapore)	Oncology	Epigenetic target			
Debio 1460	Evotec (D)	Oncology	Innovative target			
Debio 1453	Fabiotics platform[2]	STD - N. gonorrhea	FabI inhibitor			
Debio 1454	Fabiotics platform[1]	GII & UTI - Enteric species	FabI inhibitor			

[1] Debiopharm's platform

Acronyms
Hits Validated hits identified
LO Lead optimization
H2L Hit to lead
DC Select Development candidate selection

FABIOTICS PLATFORM

Our Lead Compound – Debio 1450

- First-in-class FabI inhibitor (Fatty Acid Synthesis)
- Unique selectivity against all staphylococci including MRSA, VISA, VRSA
- Expected to spare the microbiota
- Low propensity for drug resistance development
- Debio 1452:
  - demonstrated excellent clinical efficacy in phase IIa ABSSSI
- Debio 1450:
  - is a phase II prodrug of Debio 1452
  - can be administered both orally and intravenously
  - is a FDA Qualified Infectious Disease Product (QIDP)
- Expected time to market: Q2 2019
- Product is the subject-matter of pending patent applications

Debio 1450 Active in Neutropenic Mouse-Thigh Model

Dose-response was more potent than Linezolid on a mg/kg basis



Debio 1450 Conversion into Active Moiety



Fabiotics Platform

- Library of thousands compounds with high potency and good selectivity against different bacterial species
- Several co-crystals to guide the SAR
- Know-how related to the development of new compounds targeting other enzymes of the FASII pathway (FabI, FabK, FabG, FabH…)

Target Family: FabI Inhibitors

- New class of drugs: no existing resistance in nature
- Very low levels of emergence of resistance
- FabI polymorphism allow to develop selective drugs

Other Compounds in Development

Debio 1453
Discovery program to develop a small molecule inhibitor of N.gonorrhoeae FabI
Objective:
- Specific activity against Neisseria Spp.
- Need to overcome resistance problems
- Low resistance potential

Debio 1454
Discovery program to develop a small molecule inhibitor of Enteric spp. FabI
Objective:
- Narrow spectrum of activity against a combination of closely related Enteric Spp. including: E.coli, K.pneumonia, Enterobacter Spp.
- Need to overcome resistance problems
- Low resistance potential

CONTACT
Debiopharm International S.A., Lausanne, Switzerland.
www.debiopharm.com
fabien.sebille@debiopharm.com

DOWNLOAD
This poster is available via:
www.debiopharm.com/medias/publications